Biotoxtech Co. Ltd Net Assets
Biotoxtech Co. Ltd net assets. Based on the latest financial reports, Biotoxtech Co. Ltd (086040) has net assets worth ₩29.25 Billion KRW (≈ $19.82 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩130.06 Billion ≈ $88.14 Million USD) and total liabilities (₩100.81 Billion ≈ $68.32 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Biotoxtech Co. Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩29.25 Billion |
| % of Total Assets | 22.49% |
| Annual Growth Rate | 2.78% |
| 5-Year Change | -22.39% |
| 10-Year Change | 30.12% |
| Growth Volatility | 12.61 |
Net Assets of Biotoxtech Co. Ltd (2011–2025)
Net assets of Biotoxtech Co. Ltd from 2011 to 2025. This chart illustrates how Biotoxtech Co. Ltd's net assets have evolved over time, based on quarterly financial data. See how leveraged is Biotoxtech Co. Ltd's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Biotoxtech Co. Ltd (2011–2025)
The table below shows the annual net assets of Biotoxtech Co. Ltd from 2011 to 2025. For live market cap and overall valuation, see Biotoxtech Co. Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩31.93 Billion ≈ $21.64 Million |
-20.34% |
| 2024-12-31 | ₩40.08 Billion ≈ $27.16 Million |
-16.90% |
| 2023-12-31 | ₩48.23 Billion ≈ $32.69 Million |
+9.04% |
| 2022-12-31 | ₩44.23 Billion ≈ $29.98 Million |
+7.51% |
| 2021-12-31 | ₩41.14 Billion ≈ $27.88 Million |
+22.72% |
| 2020-12-31 | ₩33.53 Billion ≈ $22.72 Million |
+11.04% |
| 2019-12-31 | ₩30.19 Billion ≈ $20.46 Million |
-3.40% |
| 2018-12-31 | ₩31.25 Billion ≈ $21.18 Million |
+17.54% |
| 2017-12-31 | ₩26.59 Billion ≈ $18.02 Million |
+8.35% |
| 2016-12-31 | ₩24.54 Billion ≈ $16.63 Million |
+4.06% |
| 2015-12-31 | ₩23.58 Billion ≈ $15.98 Million |
-11.62% |
| 2014-12-31 | ₩26.68 Billion ≈ $18.08 Million |
+4.23% |
| 2013-12-31 | ₩25.60 Billion ≈ $17.35 Million |
-1.26% |
| 2012-12-31 | ₩25.93 Billion ≈ $17.57 Million |
+19.25% |
| 2011-12-31 | ₩21.74 Billion ≈ $14.73 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Biotoxtech Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 116051021000.0% over the analyzed period, indicating profitable operations and earnings retention.
Biotoxtech Co. Ltd Net Assets Breakdown (December 2025)
Biotoxtech Co. Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩1.16 Billion | 2.89% |
| Other Components | ₩39.00 Billion | 97.11% |
| Total Equity | ₩40.16 Billion | 100.00% |
Biotoxtech Co. Ltd Competitors by Market Cap
The table below lists competitors of Biotoxtech Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Radiant Globaltech Bhd
KLSE:0202
|
$20.92 Million |
|
Ken Holdings Bhd
KLSE:7323
|
$20.94 Million |
|
Deep Value Driller AS
OL:DVD
|
$20.96 Million |
|
Celulosa Argentina SA
BA:CELU
|
$21.00 Million |
|
Green Resources Public Company Limited
BK:GREEN
|
$20.91 Million |
|
2020 Bulkers Ltd
OL:2020
|
$20.89 Million |
|
ELUON Corporation
KQ:065440
|
$20.89 Million |
|
Fortuna Metals Limited
AU:FUN
|
$20.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biotoxtech Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 40,082,120,000 to 40,157,348,460, a change of 75,228,460 (0.2%).
- Net income of 1,162,772,800 contributed positively to equity growth.
- Share repurchases of 998,007,450 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩1.16 Billion | +2.9% |
| Share Repurchases | ₩998.01 Million | -2.49% |
| Other Changes | ₩-89.54 Million | -0.22% |
| Total Change | ₩- | 0.19% |
Book Value vs Market Value Analysis
This analysis compares Biotoxtech Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.81x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.24x to 0.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1705.53 | ₩2120.00 | x |
| 2017-12-31 | ₩1836.93 | ₩2120.00 | x |
| 2018-12-31 | ₩2150.46 | ₩2120.00 | x |
| 2019-12-31 | ₩2074.08 | ₩2120.00 | x |
| 2020-12-31 | ₩2297.16 | ₩2120.00 | x |
| 2021-12-31 | ₩2811.05 | ₩2120.00 | x |
| 2022-12-31 | ₩3022.25 | ₩2120.00 | x |
| 2023-12-31 | ₩3246.60 | ₩2120.00 | x |
| 2024-12-31 | ₩2549.63 | ₩2120.00 | x |
| 2025-12-31 | ₩2606.61 | ₩2120.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biotoxtech Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.47%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 3.28x
- Recent ROE (2.90%) is above the historical average (0.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 16.39% | 14.18% | 0.52x | 2.21x | ₩1.28 Billion |
| 2012 | 5.55% | 7.63% | 0.40x | 1.83x | ₩-1.09 Billion |
| 2014 | -17.44% | -30.01% | 0.32x | 1.84x | ₩-7.12 Billion |
| 2015 | -17.22% | -23.42% | 0.37x | 2.00x | ₩-6.17 Billion |
| 2016 | 4.26% | 4.69% | 0.46x | 1.96x | ₩-1.41 Billion |
| 2017 | 5.23% | 5.44% | 0.43x | 2.25x | ₩-1.27 Billion |
| 2018 | 11.60% | 13.30% | 0.43x | 2.02x | ₩498.76 Million |
| 2019 | -5.24% | -6.12% | 0.43x | 1.99x | ₩-4.60 Billion |
| 2020 | 7.80% | 9.89% | 0.42x | 1.90x | ₩-738.94 Million |
| 2021 | 17.29% | 21.74% | 0.36x | 2.21x | ₩3.00 Billion |
| 2022 | 6.16% | 7.31% | 0.30x | 2.84x | ₩-1.70 Billion |
| 2023 | -9.43% | -14.95% | 0.22x | 2.84x | ₩-10.05 Billion |
| 2024 | -16.04% | -15.55% | 0.30x | 3.40x | ₩-10.44 Billion |
| 2025 | 2.90% | 2.47% | 0.36x | 3.28x | ₩-2.85 Billion |
Industry Comparison
This section compares Biotoxtech Co. Ltd's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
Industry Context
- Industry: Biotechnology & Medical Research
- Average net assets among peers: $123,913,133,993
- Average return on equity (ROE) among peers: -12.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biotoxtech Co. Ltd (086040) | ₩29.25 Billion | 16.39% | 3.45x | $20.91 Million |
| Macrogen Inc (038290) | $177.43 Billion | -4.29% | 0.86x | $73.75 Million |
| Panagene Inc (046210) | $16.66 Billion | -24.25% | 1.30x | $28.25 Million |
| Cell Biotech Co. Ltd (049960) | $124.17 Billion | 12.18% | 0.05x | $78.69 Million |
| Bioneer Corporation (064550) | $30.61 Billion | -25.57% | 1.68x | $98.39 Million |
| MEDIPOST Co. Ltd (078160) | $252.60 Billion | -24.75% | 0.64x | $88.80 Million |
| Peptron Inc (087010) | $142.01 Billion | -9.73% | 0.26x | $1.01 Billion |
About Biotoxtech Co. Ltd
Biotoxtech Co., Ltd. engages in the safety evaluation of pharmaceuticals, foods, cosmetics, cell therapeutics, chemicals, agrochemicals, and medical equipment in South Korea. It is involved in the PK/TK, ADME, and RI analysis, as well as validation and bio analysis; efficacy evaluation and screening materials; clinical pathology and business contract of histopathology; new drug development; and b… Read more